无环鸟苷联合干扰素，双氯芬酸钠治疗单纯疱疹病毒性角膜炎

目的：观察无环鸟苷联合干扰素,双氯芬酸钠治疗单纯疱疹病毒性角膜炎的效果。方法：对160例（186眼）患者随机分为治疗组80例（97眼）和对照组80例（89例）治疗组患者滴0．1％无环鸟苷滴眼液,重组干扰素α1b滴眼液（10μg/ml）、0．1％双氯芬酸钠滴眼液,对照组滴用0．1％无环鸟苷滴眼液,结果：治疗组治愈率（91．75％）,对照治愈率（75．28％）经统计学处理,差异有显著意义（P＜0．01）;治疗组有效率（96．90％,对照组有效率（88．75％）,差异有显著意义（P＜0．05）,结论：无环鸟苷联合干扰素,双氯芬酸钠治疗单纯疱疹病毒性角膜炎疗效肯定,治愈率高,是合理安全的用药方法。     

膦甲酸钠滴眼液的制备及临床应用

目的 介绍0．5％膦甲酸钠滴眼液的处方组成、制备方法、质控标准、稳定性试验、局部刺激试验和局部毒性，观察临床疗效。方法 用0．5％膦甲酸钠治疗单纯疱疹性角膜炎。结果 总有效率82．75％。结论 本滴眼液经临床观察，疗效确切，未见不良反应。     

单纯疱疹病毒性角膜炎药物联合治疗的临床观察

目的评价华蟾素联合阿糖胞苷注射液和无环鸟苷滴眼液治疗单纯疱疹病毒性角膜炎的疗效。方法将186例(200只眼)单纯疱疹性病毒角膜炎患者随机分为治疗组106例和对照组94例,治疗组采用静脉滴注华蟾素、结膜下注射阿糖胞苷注射液和结膜囊滴用无环鸟苷滴眼液联合治疗。对照组采用上述三种治疗方法中的一种或两种。结果治疗组第一疗程治疗时间最长10天,最短3天,平均6天痊愈,治愈率为94.3％,而对照组治疗时间最长40天,最短7天,平均15．2天,治愈率为64．9％,两组相比差异有显著性(P<0．05)。结论本方法能明显缩短疗程,减少瘢痕形成,提高治愈率。     

角膜胶原膜的研制及临床应用

研究角膜胶原膜的制做方法及其在单纯疱疹病毒性角膜炎（ＨＳＫ）治疗中的应用。从猪巩膜中提取胶原采用离心干燥成膜法制成角膜胶原膜，在无环鸟苷药液内浸泡后用于治疗单纯疱疹病毒性角膜炎。结果应用浸泡无环鸟苷（ＡＣＶ）药液的胶原膜治疗组病灶平均愈合时间为９．４５天，局部滴无环鸟苷药液组病灶愈合平均时间为１４．３６天，两组治愈率和有效率分别为９０．６３％、６５．６３％和９６．８８％，８１．２５％差异显著（ｐ＜０．０５）。可见浸泡无环鸟苷药液后的胶原膜在单纯疱疹病毒性角膜炎的治疗中将具有较好的应用前景。     

无环鸟苷滴眼液联合碱性成纤维细胞生长因子滴眼液治疗单纯疱疹病毒性角膜炎疗效观察

目的 评价无环鸟苷滴眼液联合碱性成纤维细胞生长因子（重组bFGF）滴眼液治疗单纯疱疹病毒性角膜炎的疗效。方法 回顾性分析单纯疱疹病毒性角膜炎96例（96只眼）,以抗病毒药物方法治疗为对照组,共46例;抗病毒药物联合碱性成纤维细胞生长因子滴眼液为治疗组,共50例。比较两组疗效。结果两组痊愈率比较,有显著性差异（P〈0.05）。结论 无环鸟苷滴眼液联合碱性成纤维细胞生长因子滴眼液组疗效优于对照组。     

rIL-2治疗单纯疱疹性角膜炎的临床研究

目的：研究重组白细胞介素Ⅱ（rIL-2）治疗单纯疱疹性角膜炎（HSK）的疗效及预防复发的作用。方法：将确诊的HSK患者随机分为2组,治疗组38例在应用无环鸟苷滴眼液同时联合rIL-2局部及全身应用;对照组30例单纯应用无环鸟苷治疗。治愈后均随访2年。结果：联合用药治疗组的病程较对照组明显缩短（P＜0．01）。随访结果显示,治疗组的复发率较对照组明显降低（P＜0．05）。结论：临床应用rIL-2联合抗病毒药物治疗HSK疗效明显,可缩短病程、降低复发率。临床观察无明显不良反应。     

单克隆抗体联合基因工程干扰素α—1治疗单疱性角膜炎

应用抗单纯疱疹病毒（ＨＳＶ）糖蛋白单克隆抗体和基因工程人干扰素α—１两种滴眼液联合用药对比无环鸟苷滴眼液观察治疗单纯疱疹病毒性角膜炎１１２例的疗效。结果，联合用药组全部治愈，复发率明显低于无环鸟苷治疗组和单独应用干扰素治疗组（Ｐ＜０．０５）。并对无环鸟苷无效的病例，对伴有角膜溃疡的病例，能促进其角膜基质的修复和上皮生长，无过敏或毒性反应，提高了疗效，缩短了疗程，为治疗单疱角膜炎提供了一条新途径。     

膦甲酸钠滴眼液治疗上皮型单纯疱疹病毒性角膜炎

目的：探讨膦甲酸钠滴眼液治疗上皮型单纯疱疹病毒性角膜炎（herpes simplex keratitis,HSK）的近中期疗效。 方法：选取2008-03/2009-12在钟祥市人民医院眼科门诊确诊的60例60眼上皮型HSK患者,将其随机分为对照组和试验组两组。对照组采用更昔洛韦滴眼液,8次/d;试验组采用膦甲酸钠滴眼液,6次/d,用药时间均为14d。观察治疗后3,7,10,14d的角膜溃疡面积、眼部症状体征评分,统计治愈率。随访2a,统计随访期间上皮型HSK的复发率。 结果:两组患者治疗前的一般情况、症状体征评分无显著差异（P>0.05）。与治疗前相比,治疗后两组患者的角膜溃疡面积、眼部症状体征评分均明显下降（P<0.05）,但两组之间的角膜溃疡面积、眼部症状体征评分和治愈率均无明显差异（P>0.05）。随访2a期间,试验组和对照组患者的复发率分别是13%,27%,差异有显著性（P<0.05）。 结论:膦甲酸钠滴眼液在治疗上皮型HSK的近期疗效与更昔洛韦滴眼液相同,但中期复发率低于更昔洛韦滴眼液。     

0.1%无环鸟苷滴眼液点眼致角膜上皮剥脱一例

０．１％无环鸟苷滴眼液点眼致角膜上皮剥脱一例杨国雄崔友（平顶山市第四人民医院，４６７０００）患者男，４６岁，因左眼轻度异物感、畏光、流泪于１９９７年１１月２４日来我院眼科就诊，诊断为单纯疱疹性结、角膜炎，局部给予０．１％无环鸟苷滴眼液点眼。患者归家后...     

鱼腥草联合干扰素滴眼治疗单纯疱疹病毒性角膜炎的疗效评价

目的 评价鱼腥草联合干扰素（滴宁）滴眼液治疗单纯疱疹病毒性角膜炎（HSK）的临床疗效。方法 治疗组60例67眼HSK患者联合滴用鱼腥草滴眼液和干扰索滴眼液，并观察静脉滴注鱼腥草注射液的临床疗效，与对照组38例43眼HSK患者用阿昔洛韦滴眼液及静脉滴病毒唑注射液进行对比，比较其治愈率、有效率、疗程及复发率。结果 治疗组治愈59眼，治愈率为88．06％，有效6眼，有效率8．96％，无效2眼（深层型），治疗天数平均19天，随访1年54眼中复发5眼，复发率9．26％；对照组治愈25眼，治愈率58．14％，有效12眼，有效率27．91％，无效6眼，治疗平均天数31天，随访1年23眼复发7眼，复发率30．43％；两者比较治疗组疗程和疗效均优于对照组（P〈0．01），治愈患者随访1年，治疗组复发率比对照组明显低。结论 临床应用鱼腥草联合干扰素（滴宁）滴眼液治疗单纯疱疹病毒性角膜炎能提高疗效，缩短病程，降低复发率，具有较好的治疗和抗复发效果，从而降低致盲率。     

口服阿昔洛韦联合玻璃酸钠及氟米龙眼液治疗带状疱疹性角膜炎

目的：探讨口服阿昔洛韦联合玻璃酸钠及氟米龙眼液滴眼治疗带状疱疹性角膜炎疗效。

方法：将本院收治的40例眼部带状疱疹患者分为两组,观察组20例,对照组20例。观察组应用阿昔洛韦200mg口服,5次/d,玻璃酸钠眼液点眼,4次/d,当发生角膜基质炎、盘状角膜炎或者角膜内皮炎时使用1g/L氟米龙眼液点眼,4次/d; 对照组给予1.5g/L更昔洛韦眼用凝胶滴眼4次/d。随访3～4wk,观察两组患者的疗效。

结果：观察组在患者局部疼痛及畏光缓解时间、角膜损伤愈合时间与对照组比较,观察组均优于对照组,差异有统计学意义(P<0.05); 两组有效率比较,差异无统计学意义(P=0.633)。

结论：口服阿昔洛韦联合玻璃酸钠及氟米龙眼液治疗带状疱疹性角膜炎疗效满意。     

Geldanamycin is effective in the treatment of herpes simplex virus epithelial keratitis in a rabbit model

Background: To evaluate the efficacy of geldanamycin eye drops against herpes simplex virus epithelial keratitis in a rabbit model. Methods: New Zealand white rabbits were randomized into four groups and infected with herpes simplex virus type 1; geldanamycin topical eye drops was initiated 24 h after the infection and maintained for 12 consecutive days. Four groups of rabbits received 5 µg/mL geldanamycin, 10 µg/mL geldanamycin, 0.1% acyclovir and escipient (a kind of artificial tears), respectively. The severity of herpes simplex virus type 1 epithelial keratitis was measured by slit‐lamp and scored for statistics analysis. The virus shedding in eye swabs was isolated, and tissue culture infective dose (TCID₅₀) was determined. Results: Geldanamycin (10 µg/mL) treatment reduced significantly the severity of herpes simplex virus type 1 epithelial keratitis than the other three groups. Geldanamycin (5 µg/mL) was as effective as acyclovir (0.1%) treatment. The effect of geldanamycin against herpes simplex virus type 1 epithelial keratitis correlated with accelerated clearance of virus of the rabbits. Conclusion: Geldanamycin is a promising treatment option against herpes simplex virus type 1 epithelial keratitis. Geldanamycin (10 µg/mL) is better than acyclovir and geldanamycin (5 µg/mL) in the rabbit model. The optimal concentration of this drug in human is still to be determined.     

益气养血祛风法治疗复发性单纯疱疹病毒性角膜炎的临床观察

目的:观察运用益气养血祛风法(黑睛退翳汤)治疗复发性单纯疱疹病毒性角膜炎(HSK)的临床疗效.方法:入选复发的HSK患者58例,随机分为治疗组和对照组.对照组给予重组人干扰素α-2b滴眼液和更昔洛韦眼用凝胶,对于具有虹膜睫状体炎症及角膜内皮炎症的患者给予复方托吡卡胺滴眼液散瞳治疗,酌情给予氟米龙滴眼液滴眼;治疗组在对照组的基础上加用黑睛退翳汤治疗4wk,观察两组临床疗效及治愈的患者治愈后6mo内疾病复发率情况.结果:两组患者治疗后临床疗效、疾病复发率比较差异均有统计学意义(P<0.05),治疗1 mo后,治疗组CD4+及CD4+/CD8+比值明显升高,均显著高于对照组(P<0.01),治疗组CD8+比例显著降低,与对照组比较差异显著(P<0.01).结论:益气养血祛风法中药黑睛退翳汤联合常规抗病毒西药治疗,能更好地治疗HSK并预防其复发,提高临床疗效,改善患者生活质量.     

典必殊联合阿昔洛韦治疗单疱病毒性角膜炎的疗效观察

目的:探讨典必殊滴眼液联合阿昔洛韦(无环鸟苷,ACV)滴眼液治疗单疱病毒性角膜炎(herpes simplex keratitis,HSK)的疗效。方法:将43例46眼HSK患者随机分两组,典必殊治疗组23例25眼,贝复舒对照组20例21眼,将其临床资料进行回顾性分析,观察临床治疗效果。结果:浅层型全部治愈,深层型典必殊治疗组有效率87.5%,贝复舒对照组有效率60.0%,治愈时间典必殊治疗组平均12d,贝复舒治疗组平均17d;复发率典必殊治疗组34.8%,贝复舒对照组55.0%。两组相比差异有统计学意义(P<0.05)。结论:典必殊联合阿昔洛韦治疗HSK,具有明显的协同作用,能提高治愈率,缩短病程,降低复发,尤其对深层型单疱病毒性角膜炎疗效显著。     

环孢霉素A滴眼液治疗单疱病毒性角膜基质炎疗效观察

目的:观察10g/L环孢霉素A滴眼液治疗单疱病毒性角膜基质炎临床疗效。方法:我院2011-01/2012-01治疗单疱病毒性角膜基质炎患者91例91眼,随机分为两组,A组应用10g/L环孢霉素A滴眼液和更昔洛韦凝胶,B组应用5g/L氯替泼诺滴眼液和更昔洛韦凝胶,其余均为对症治疗,随诊观察6～12(平均10)mo。结果:两组治疗单疱病毒性角膜基质炎疗效无显著性差异,但A组治愈时间平均5.1±2.4d,B组治愈时间平均6.2±2.8d,A组较B组平均治愈时间短。两组治愈率及复发率无统计学差异。结论:对于单疱病毒性角膜基质炎患者应用10g/L环孢霉素A滴眼液能够安全有效治愈,且治愈时间短。     

Herpes simplex keratitis after ophthalmic surgery

PURPOSE: We report 6 cases of herpes simplex keratitis after ophthalmic surgery, in eyes without clinical history of herpes simplex keratitis. CASES: These cases comprised 6 patients examined at our hospital between April 1992 and November 2001. Past operations were keratoplasty in 5 eyes and cataract surgery in 1 eye. Clinical findings and predisposing factors were evaluated retrospectively. The period between herpetic epithelial keratitis onset and ophthalmic surgery ranged from 1.5 to 79 months. Predisposing factors included corticosteroid therapy and operative wound. The herpetic epithelial lesions were dendritic ulcers in 2 eyes, geographic ulcer in 1 eye, and atypical epithelial lesions in 3 eyes; in all cases, herpes simplex virus (HSV)-DNA was detected by polymerase chain reaction (PCR) in tear fluid. All herpetic epithelial lesions healed with oral and topical acyclovir. CONCLUSIONS: When corticosteroids are used following ophthalmic surgery, physicians should be alert to the possibility of herpetic epithelial keratitis, even in patients with no clinical history of herpes simplex keratitis. PCR detection in tear fluid is helpful in diagnosing this disease.     

Light adaptation and the luminance-response function of the cone electroretinogram

Corneal graft survival in 13 patients (14 eyes) receiving oral acyclovir following corneal transplantation for herpes simplex keratitis was compared to that in nine patients (9 eyes) who underwent penetrating keratoplasty for herpes simplex keratitis without receiving postoperative acyclovir. Mean age, duration of disease, and time of follow-up did not differ in the two groups. There were no recurrences of herpes simplex keratitis in any patient receiving acyclovir during a mean follow-up of 16.5 months compared to a 44% (4/9) recurrence rate in patients without acyclovir during a mean follow-up of 20.6 months (p < 0.01). Graft failure occurred in 14% (2/14) of acyclovir treatment eyes and in 56% (5/9) of the grafts in patients not receiving acyclovir. Long term prophylactic oral acyclovir significantly decreased the recurrence of herpes simplex keratitis and reduced corneal graft failure in patients with a history of recurrent herpes simplex keratitis who underwent corneal transplantation.Abbreviations ACV acyclovir - HSK herpes simplex keratitis - PK penetrating keratoplasty Presented as a paper at The American Academy of Ophthalmology, annual meeting in Anaheim, California 13–17 October 1991.     

球结膜下注射转移因子在治疗单纯疱疹病毒性角膜炎的临床应用

目的观察球结膜下注射转移因子对治疗单纯疱疹病毒性角膜炎（ HSK）的疗效。方法86例（92只眼）HSK患者随机分成两组。 A组（45例49只眼）予球结膜下注射转移因子,B组（41例43只眼）予球结膜下注射α-干扰素及α-干扰素滴眼,两组均常规滴用阿昔洛韦滴眼液。结果 A组疗效优于B组（ P ＜0．05）。结论球结膜下注射转移因子可以提高患眼局部免疫力,配合抗病毒治疗HSK效果好,操作简单,无明显副作用。